Original Research

Published on 25 Jan 2022

Development and Validation of a Prognostic Index Based on Genes Participating in Autophagy in Patients With Lung Adenocarcinoma

in Cancer Molecular Targets and Therapeutics

Zi-Xuan Wu
Xuyan Huang
Min-Jie Cai
Pei-Dong Huang
Zunhui Guan

Frontiers in Oncology

doi 10.3389/fonc.2021.799759

5,391 views
12 citations

Original Research

Published on 24 Jan 2022

Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

in Cancer Molecular Targets and Therapeutics

Yee Kit Tai
Karen Ka Wing Chan
Charlene Hui Hua Fong
Sharanya Ramanan
Jasmine Lye Yee Yap
Jocelyn Naixin Yin
Yun Sheng Yip
Wei Ren Tan
Angele Pei Fern Koh
Nguan Soon Tan

Frontiers in Oncology

doi 10.3389/fonc.2021.783803

10,066 views
14 citations

Original Research

Published on 24 Jan 2022

Pan-Cancer Analyses Reveal Oncogenic Role and Prognostic Value of F-Box Only Protein 22

in Cancer Molecular Targets and Therapeutics

Sen Chen
Shuangxin Ma
Jiaoyan Yan
Haiqing Wang
Bojiao Ding
Zihu Guo
Yaohua Ma
Xuetong Chen
Yonghua Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.790912

4,708 views
7 citations

Review

Published on 19 Jan 2022

The Emerging Landscape of Long Non-Coding RNAs in Wilms Tumor

in Cancer Molecular Targets and Therapeutics

Qiang Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.780925

1,712 views
1 citation

Mini Review

Published on 17 Jan 2022

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

in Cancer Molecular Targets and Therapeutics

Luyao Wang
Yurong Chen
Xinrui Liu
Ziyi Li
Xiangpeng Dai

Frontiers in Oncology

doi 10.3389/fonc.2021.704999

12,080 views
17 citations

Review

Published on 12 Jan 2022

Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway

in Cancer Molecular Targets and Therapeutics

Yusheng Guo
Guohui Wu
Junrong Yi
Qin Yang
Wengong Jiang
Shaoqiang Lin
Xiaorong Yang
Xiangsheng Cai
Liufeng Mao

Frontiers in Oncology

doi 10.3389/fonc.2021.763539

4,691 views
13 citations

Review

Published on 11 Jan 2022

Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis

in Cancer Molecular Targets and Therapeutics

Ting Wen
Qiao Yi Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.806974

4,199 views
4 citations

Original Research

Published on 10 Jan 2022

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population

in Cancer Molecular Targets and Therapeutics

Yajun Wang
Lan Yao
Yao Teng
Hua Yin
Qiuling Wu

Frontiers in Oncology

doi 10.3389/fonc.2021.783583

3,018 views
6 citations

Correction

Published on 07 Jan 2022

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

in Cancer Molecular Targets and Therapeutics

Fang Wei
Mofei Wang
Zhen Li
Yong Wang
Yong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.818876

1,483 views

Original Research

Published on 07 Jan 2022

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

in Cancer Molecular Targets and Therapeutics

Michael S. Gordon
Geoffrey I. Shapiro
John Sarantopoulos
Dejan Juric
Brian Lu
Angeliki Zarotiadou
Jamie N. Connarn
Yvan Le Bruchec
Calin Dan Dumitru
R. Donald Harvey

Frontiers in Oncology

doi 10.3389/fonc.2021.786120

2,852 views
8 citations

Clinical Trial

Published on 07 Jan 2022

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

in Cancer Molecular Targets and Therapeutics

Ryunosuke Nakagawa
Hiroaki Iwamoto
Tomoyuki Makino
Suguru Kadomoto
Hiroshi Yaegashi
Masashi Iijima
Shohei Kawaguchi
Takahiro Nohara
Kazuyoshi Shigehara
Kouji Izumi

Frontiers in Oncology

doi 10.3389/fonc.2021.770067

6,059 views
5 citations

Mini Review

Published on 07 Jan 2022

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

in Cancer Molecular Targets and Therapeutics

Farbod Shojaei
Bob Goodenow
Gloria Lee
Fairooz Kabbinavar
Mireille Gillings

Frontiers in Oncology

doi 10.3389/fonc.2021.768685

4,793 views
2 citations

Original Research

Published on 06 Jan 2022

Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation

in Cancer Molecular Targets and Therapeutics

Huihui Ji
Kehan Li
Wenbin Xu
Ruyi Li
Shangdan Xie
Xueqiong Zhu

Frontiers in Oncology

doi 10.3389/fonc.2021.780387

4,856 views
15 citations

Review

Published on 06 Jan 2022

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

in Cancer Molecular Targets and Therapeutics

Timothy A. Yap
Ira Jacobs
Elodie Baumfeld Andre
Lauren J. Lee
Darrin Beaupre
Laurent Azoulay

Frontiers in Oncology

doi 10.3389/fonc.2021.695936

12,198 views
27 citations

Review

Published on 06 Jan 2022

Crosstalk Among YAP, LncRNA, and Tumor-Associated Macrophages in Tumorigenesis Development

in Cancer Molecular Targets and Therapeutics

Jing Xu
Xin-Yuan Liu
Qi Zhang
Hua Liu
Peng Zhang
Zi-Bin Tian
Cui-Ping Zhang
Xiao-Yu Li

Frontiers in Oncology

doi 10.3389/fonc.2021.810893

4,385 views
12 citations

Original Research

Published on 06 Jan 2022

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

in Cancer Molecular Targets and Therapeutics

Massimiliano Bonifacio
Cristina Papayannidis
Federico Lussana
Nicola Fracchiolla
Mario Annunziata
Simona Sica
Mario Delia
Robin Foà
Giovanni Pizzolo
Sabina Chiaretti

Frontiers in Oncology

doi 10.3389/fonc.2021.804714

4,206 views
14 citations

Navigation group

Articles

Development and Validation of a Prognostic Index Based on Genes Participating in Autophagy in Patients With Lung Adenocarcinoma

Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

Pan-Cancer Analyses Reveal Oncogenic Role and Prognostic Value of F-Box Only Protein 22

The Emerging Landscape of Long Non-Coding RNAs in Wilms Tumor

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway

Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation

Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development

Crosstalk Among YAP, LncRNA, and Tumor-Associated Macrophages in Tumorigenesis Development

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia